What are the recommendations for prophylactic antiviral therapy in patients with hepatitis B (HBV) (Hep B)?

Updated: Aug 01, 2018
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Close monitoring during and for several months after therapy with immunosuppressive drugs is appropriate. If reactivation of hepatitis B occurs, stopping the agent and initiating antiviral therapy may be warranted. Various national organizations including the AASLD and the National Institutes of Health (NIH) recommend the use of prophylactic antiviral therapy in inactive HBsAg carriers who are to undergo antineoplastic or immunosuppressive therapy. [2, 55, 104]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!